



✉ EPA/EPO/OEB
D-80298 München
☎ +49 89 2399-0
TX 523 656 epmu d
FAX +49 89 2399-4465

**Europäisches
Patentamt**

Generaldirektion 2

**European
Patent Office**

Directorate General 2

**Office européen
des brevets**

Direction Générale 2

Vossius & Partner
Siebertstrasse 4
81675 München
ALLEMAGNE

Telephone numbers:

Primary Examiner +49 89 2399-8785
(substantive examination)

Formalities Officer / Assistant +49 89 2399-5762
(Formalities and other matters)



Application No. 04 772 194.9 - 2405	Ref. M1335 EP S3	Date 15.11.2007
Applicant TAKARA BIO INC.		

Communication pursuant to Article 96(2) EPC

The examination of the above-identified application has revealed that it does not meet the requirements of the European Patent Convention for the reasons enclosed herewith. If the deficiencies indicated are not rectified the application may be refused pursuant to Article 97(1) EPC.

You are invited to file your observations and insofar as the deficiencies are such as to be rectifiable, to correct the indicated deficiencies within a period

of 4 months

from the notification of this communication, this period being computed in accordance with Rules 78(2) and 83(2) and (4) EPC.

One set of amendments to the description, claims and drawings is to be filed within the said period on separate sheets (Rule 36(1) EPC).

Failure to comply with this invitation in due time will result in the application being deemed to be withdrawn (Article 96(3) EPC).



Obel, Nicolai
Primary Examiner
for the Examining Division

Enclosure(s): 5 page/s reasons (Form 2906)

**Bescheid/Protokoll (Anlage)**

Datum
Date 15.11.2007
Date

Communication/Minutes (Annex)

Blatt
Sheet 1
Feuille

Notification/Procès-verbal (Annexe)

Anmelde-Nr.:
Application No.: 04 772 194.9
Demande n°:

The examination is being carried out on the following application documents:

Description, Pages

1-189 as originally filed

Sequence listings, Pages

1-46 as originally filed

Claims, Numbers

1-20 received on 29.08.2007 with letter of 29.08.2007

Drawings, Sheets

1 as originally filed

1. New claims 1-20 filed with your letter dated 29.08.2007 are not allowable under Article 123(2) EPC.

1.1 Claim 1 of the amended claims is describing subject matter beyond the application as filed. The claim refers to SEQ ID NO 9 to 20 and 25 or "a polypeptide comprising at least one amino acid sequence having substitution, deletion, insertion or addition of one or the plural number of amino acids in any one of said amino acid sequences wherein the polypeptide (n) has a function equivalent to that of said polypeptide (m)". The basis is claimed to be found in claims 10 and 12 of the original set of claims.

**Bescheld/Protokoll (Anlage)**

Datum
Date 15.11.2007
Date

Communication/Minutes (Annex)

Blatt
Sheet 2
Feuille

Notification/Procès-verbal (Annexe)

Anmelde-Nr.:
Application No.: 04 772 194.9
Demande n°:

However, the variants of the sequences are described in claim 10 and are with regard to SEQ ID NO 1-8. No variants of SEQ ID NO 9 and 20-25 are disclosed in claim 12 of the original set of claims. The fact that the original claim 12 was dependent on claim 10 can not serve as a basis as SEQ ID NO 9 and 20-25 represent specific embodiments within the scope of claim 10 of the original set of claims. The amendment describes thus subject matter beyond the application as filed.

- 1.2 The claims 1,6,13,14 and 15 are directed to a method using "a fibronectin fragment or a mixture thereof", see also 4.2. The original set of claims were describing "fibronectin, a fragment thereof or a mixture thereof". The basis is thus disclosing a mixture of fibronectin and a fibronectin fragment. The amended set of claims can only be seen as describing a mixture of at least two different fibronectin fragments and describe thus subject matter beyond the application as filed.
2. The present application does not meet the requirements of Article 52(1) EPC, because the subject-matter of claims 1,3-10,15 and 16 is not new in the sense of Article 54(1) and (2) EPC.
 - 2.1 It is acknowledged that the amendments to claims 1 and 15 render the subject matter novel with regard to D1,D2,D5 and D7 as a serum concentration in the range 0-4% is not disclosed in said documents. Furthermore, the protein and nucleic acid sequences disclosed in the amended claims 18-20 is not disclosed in D3 and D4.
 - 2.2 In the letter of 29.08.07, the applicant argues that D6 does not disclose the new features in the amended claim 1 which refer to the expansion of cells and the use of fibronectin fragments. However this is not correct as D6 (col 19 l. 61- col 20 l. 45) discloses a method of growing cytotoxic lymphocytes such as LAK's in the presences of an extracellular matrix protein such as fibronectin placed on a membrane. D6 (col 31 l. 51 - col 32 l. 4) discloses also that cells were bound to a proteolytic fragment of fibronectin and the binding was inhibited by 90% by RGDS, the central binding site of fibronectin (D6, col 32 l. 65 - col 33 l. 37). The document discloses thus that the binding was restricted to distinct fragments of fibronectin. D6 states also that serum free medium can be used (col 5 l. 15-28) and that mainly CD8+ cells were generated (col 16 l. 49-61, col 26 l. 10-21, col 30 l. 23-28).

**Bescheld/Protokoll (Anlage)**

Datum
Date 15.11.2007
Date

Communication/Minutes (Annex)

Blatt
Sheet 3
Feuille

Notification/Procès-verbal (Annexe)

Anmelde-Nr.:
Application No.: 04 772 194.9
Demande n°:

D6 is directed to a method of providing activated T-lymphocytes for use in therapy. The vague definition of the fibronectin fragments to be used in the method, which is not conform with Article 123(2) and 84 EPC, see 1.1 and 4.1, means that no limitations with regard to the indicated sequences exist beyond the fibronectin annotation. D6 anticipates thus the subject matter of claims 1,3-10,15 and 16 of the amended set of claims.

3. The present application does not meet the requirements of Article 52(1) EPC, because the subject-matter of claims 2,11-14 and 17-20 does not involve an inventive step in the sense of Article 56 EPC.
- 3.1 The document D6 is regarded as being the closest prior art to the subject-matter of claims 2,11-14 and 17, see 2.2.

The subject matter of claim 2 is directed to a method for providing cytotoxic lymphocytes by expanding the cells on fibronectin fragments and thereby increase the expression of the IL-2 receptor.

The subject-matter of claim 2 therefore differs from this known (D6) in that the method provides a higher expression of the IL-2 receptor.

The problem to be solved can thus be regarded at to provide an improved method for providing cytotoxic lymphocytes.

D6 already provides a method for expanding cytotoxic lymphocytes on fibronectin fragments and D5 (abstract) discloses that exposure to fibronectin increased the expression of the IL-2 receptor. The subject matter of claim 2 is thus not regarded as inventive in the sense of Article 56 EPC.

In the letter of 29.08.2007, the applicant argues that surprising effects arise from the disclosed method. These effects are a high expression of the IL-2 receptor, an increased expansion rate, increased cytotoxicity and higher ratio of CD8+ cells. If such improvements were clearly demonstrated with regard to the prior art an inventive step could be acknowledged. However, no surprising effects have been

**Bescheld/Protokoll (Anlage)**

Datum
Date 15.11.2007
Date

Communication/Minutes (Annex)

Blatt
Sheet 4
Feuille

Notification/Procès-verbal (Annexe)

Anmelde-Nr.:
Application No.: 04 772 194.9
Demande n°:

substantiated with data, documenting said alleged effects.

- 3.2 D1,D5 and D7 do not anticipate claims 1 and 15 of the amended set of claims. However, the only difference to these documents and the subject matter of claim 1 is the lowering of the serum concentration from 5% to 4%. The objective problem to be solved with regard to said documents would thus be how to provide an alternative method for producing cytotoxic lymphocytes. Since it is evident for the person skilled in the art that it is beneficial for patients if less serum is used, the lowering of the serum concentration from 5% to 4% can not be considered inventive. Similar to 3.1, an inventive step with regard to said claims can be acknowledged if a surprising or unexpected effect is documented.
- 3.3 Claims 11-14 is directed to specific steps and concentrations of cells when culturing the cytotoxic lymphocytes. Said steps and concentrations are all normally used in the art and in view of 3.1 the subject matter is not inventive in the sense of Article 56 EPC.
- 3.4 Claim 17 differs from D6 in the use of retro-virus or adeno-associated virus for gene transduction. These methods for gene transduction are merely some of several straightforward possibilities from which the skilled person would select, in accordance with circumstances, without the exercise of inventive skill, in order to solve the problem posed. In view of 3.1, the subject matter of claim 17 is not inventive in the sense of Article 56 EPC.
- 3.5 The subject matter of claims 18-20 differs from the prior art (D4) in that only a partial sequence of the fibronectin disclosed in D4 is selected. D4 (p. 3 l. 8-22) states that also fragments extending from the core 277-577 amino acids are encompassed by D4. The subject matter of claims 18-20 is thus merely representing an arbitrary selection of the sequence disclosed in D4. No surprising or unexpected effect has been documented for this molecule with regard to other fibronectin fragments and the subject matter is thus not inventive in the sense of Article 56 EPC.
4. The application does not meet the requirements of Article 84 EPC, because claims 1,6 and 15 are not clear.

**Bescheld/Protokoll (Anlage)**

Datum
Date
Date 15.11.2007

Communication/Minutes (Annex)

Blatt
Sheet
Feuille 5

Notification/Procès-verbal (Annexe)

Anmelde-Nr.:
Application No.: 04 772 194.9
Demande n°:

- 4.1 If a basis is indicated for the amended claim 1 in its present form, the applicant should notice that the claim is not clear due to the term "at least one amino acid sequence having substitutions, deletions, insertions or additions of one or more plural number of amino acids". This term is not suitable to clearly define the scope of the claim, because without definition of the length of the fragment, degree of identity and precise definition of the meant portion of the molecule this expression is absolutely vague and ambiguous. The claim encompass all fibronectin fragments regardless of the indicated sequences.
- 4.2 Claims 1,6 and 15 are not clear as they are directed to "a fibronectin fragment or a mixture thereof". The indicated "mixture thereof" is not clear as it can not be ascertained what the mixture consists of as only a fibronectin fragment, i.e one fragment, is indicated as being used for cell expansion.
5. The applicant is requested to file new claims which take account of the above comments. The attention of the Applicant is drawn to the fact that the application may not be amended in such a way that it contains subject-matter which extends beyond the content of the application as filed, Article 123(2) EPC.

VOSSIUS & PARTNER



Patentanwälte Rechtsanwälte

EPO - Munich
40

29. Aug. 2007

VOSSIUS & PARTNER * POB 86 07 67 * 81634 München * Germany

European Patent Office

80298 MUNICH

EP 04 77 2194.9-2405

Takara Bio Inc.

Our Ref.: M1335 EP S3

Munich, August 29, 2007

SZ/AF

This is in response to the Communication pursuant to Article 96(2)
EPC dated February 20, 2007.

Enclosed please find new claims 1 to 20 which should form the basis for further substantive examination. We herewith reserve our right to file divisional applications for subject matter which was deleted from the claims or which is no longer covered by the new claims.

1. AMENDMENTS IN THE CLAIMS

1.1 New claim 1 is based on original claim 1 which has been amended as follows:

- (i) The term "a cytotoxic lymphocyte" has been corrected to "cytotoxic lymphocytes".
- (ii) The phrase "at least one step selected from induction, maintenance and" has been deleted and the term "an" has been inserted before "expansion".

PATENTANWÄLTE

EUROPEAN PATENT ATTORNEYS

EUROPEAN TRADEMARK ATTORNEYS

DR. VOLKER VOSSIUS, Dipl.-Chem.
(bis 1992; danach in anderer Kanzlei)
DR. PAUL TAUCHNER, Dipl.-Chem.
DR. DIETER HEUNEMANN, Dipl.-Phys. *
DR. PETER A. RAUH, Dipl.-Chem.
DR. GERHARD HERMANN, Dipl.-Phys.
JOSEF SCHMIDT, Dipl.-Ing.
DR. HANS-RAINER JAENICHEN, Dipl.-Biol.
DR. ALEXA V. UEXKÜLL, M.Sc.
DR. RUDOLF WEINBERGER, Dipl.-Chem.
AXEL STELLBRINK, Dipl.-Ing.
DR. JOACHIM WACHENFELD, Biol.
DR. FRIEDRIKE STOLZENBURG, Dipl.-Biol.
RAINER VIKTOR, Dipl.-Ing.
DR. NATALIA BERRYMAN, Dipl.-Chem.
DR. JÖRGEN MEIER, Dipl.-Biol.
DR. STEFAN FICKERT, Dipl.-Chem.
ARNOLD ASMUSSEN, Dipl.-Ing.
ELARD SCHENCK ZU SCHWEINSBERG, Dipl.-Ing.
DR. KATHARINA HAAS, Dipl.-Chem.
DR. CHRISTIAN KILGER, Dipl.-Biol. *
DR. UTE KILGER, Dipl.-Chem. *
DR. DIRK HARMSEN, Dipl.-Chem.

EUROPEAN PATENT ATTORNEYS

DR. RENATE BARTH, Dipl.-Chem.
DR. URSULA ENGBRECHT, Dipl.-Chem.
DR. PETER EINMAYR, Dipl.-Chem.
DR. WERNER BASTIAN, Dipl.-Biol. **
DR. OLAF MALEK, Dipl.-Biol.
DR. MICHAELA WESSE, Apothekerin
DR. ANDREAS KOCH, Dipl.-Biol.
DR. OLIVER SAHR, Dipl.-Phys.
DR. GERHARD WEINZIERL, Dipl.-Biol.
DR. AXEL LEINS, Dipl.-Phys.
THOMAS RITTER, Ph.D., M.Sc.

RECHTSANWÄLTE

DR. JOHANN PITZ
BARBARA GUGGENMOS, Dipl.-Chem.
DR. THURE SCHUBERT
SIMONE SCHÄFER
JENNIFER CLAYTON-CHEN
DR. NIELS HOLDER, LL.M.
DR. MATHIAS KLEESPIES, LL.M.

CONSULTANTS

HELGA TREMMEL, RECHTSANWÄLTIN
DR. CHRISTIAN GUGERELL,
EUROPEAN PATENT ATTORNEY
YOSHIKAZU ISHINO
KIMIO TAKAHASHI

MAIN OFFICE

SIEBERTSTR. 3
81675 MÜNCHEN/GERMANY

POSTAL ADDRESS:

POB 86 07 67
81634 MÜNCHEN/GERMANY

Tel.: +49-(0)89-413 04-0
Fax: +49-(0)89-413 04-111
Fax trademarks: /-400

BRANCH OFFICE BERLIN *

JOACHIMSTALER STR. 34
10719 BERLIN/GERMANY

Tel.: +49-(0)30-340 609-501
Fax: +49-(0)30-340 609-512

Partnerschaftsregister Amtsgericht München PR 89

BRANCH OFFICE BASEL (CH) **

GRELLINGERSTR. 60
4052 BASEL/SWITZERLAND

Tel.: +41-(0)61 560 1490
Fax: +41-(0)61 560 1488

HR Firmennummer CH-270.9.001.271-9

E-Mail:

patents@vossiusandpartner.com
trademarks@vossiusandpartner.com

www.vossiusandpartner.com

- (iii) "5% by volume" has been amended to "4% by volume".

Support for this amendment can be found, e.g. on page 22, lines 22 to 24 of the application.

- (iv) The phrase "fibronectin, a fragment thereof or a mixture thereof" has been restricted to "a fibronectin fragment or a mixture thereof".
- (v) Moreover, the fibronectin fragment has been further specified as one consisting of SEQ ID NOs: 9 to 20 or 25 or as a polypeptide deviation from these fragments but having a function equivalent to SEQ ID NOs: 9 to 20 or 25.

Support for this amendment can be found, e.g., in original claims 10 and 12.

- 1.2 New claims 2 to 5 correspond to original claims 2 to 5 with the only exception that the following amendments have been effected:

- (i) The term "cytotoxic lymphocyte" has been corrected to "cytotoxic lymphocytes".
- (ii) It has been clarified that the method is for preparing cytotoxic lymphocytes with the indicated activities/properties.

- 1.3 New claim 6 corresponds to original claim 6 which has been restricted to the fibronectin fragments mentioned in claim 1.

- 1.4 New claims 7 and 8 correspond to original claims 7 and 8.

- 1.5 New claim 9 corresponds to original claim 9 with the only exception that the singular has been corrected to plural.

- 1.6 Original claim 10 has been deleted.

- 1.7 New claim 10 corresponds to original claim 11 with the back reference adjusted.

- 1.8 Original claim 12 has been deleted.

- 1.9 New claim 11 corresponds to original claim 13.

- 1.10 New claim 12 corresponds to original claim 14 with the back reference adjusted.

- 1.11 New claims 13 and 14 correspond to original claims 15 and 16, respectively, wherein "at least any one of induction, maintenance and" has been deleted, "an" has been inserted before "expansion", "a cytotoxic lymphocyte" has been corrected to "cytotoxic lymphocytes" and the claims have been restricted to fibronectin fragments.
- 1.12 Original claims 17 and 18 have been deleted.
- 1.13 New claim 15 corresponds to original claim 19 in which the same amendments as set forth in section 1.1(i), (iii) and (iv) for claim 1 have been effected.
- 1.14 New claim 16 corresponds to original claim 20 in which "a cytotoxic lymphocyte" has been corrected to "cytotoxic lymphocytes" and the back reference has been adjusted.
- 1.15 New claim 17 corresponds to original claim 21 with the back reference adjusted.
- 1.16 New claim 18 corresponds to original claim 22 in which the term "having" has been replaced by "consisting of" and the phrase "of one or the plural number of amino acid(s)" has been replaced by "of 1-20 amino acids".
Support for the latter amendment can, e.g. be found on page 48, lines 1 to 5 of the application.
- 1.17 New claim 19 corresponds to original claim 23 with the back reference adjusted.
- 1.18 New claim 20 corresponds to original claim 24 with the exception of the following amendments:
- (i) The "comprising" language has been replaced by "consisting" language.
 - (ii) The back reference has been adjusted.
 - (iii) The phrase "of one or the plural number of nucleotide(s)" has been replaced by "of 1-60 nucleotides".
This amendment is, e.g., supported by the disclosure content provided on page 48, last line to page 49, line 4.
 - (iv) Part (3) has been deleted.

For the convenience of the Examiner we enclose a copy of the claims from which the effected amendments are evident.

2. NOVELTY (ARTICLE 54 EPC)

2.1 Claims 1 and 19 (new claims 1 and 15)

(a) EP-A1 1 424 387 (D1)

In section 2.1 of the Communication original claims 1 and 19 are objected to as lacking novelty over EP-A1 1 424 387 (D1) in particular in view of the disclosure provided in paragraph 165 in combination with paragraph 77 and in view of claim 8 of D1.

This novelty objection does not apply to the new claims. It has been specified in the claims that the serum and plasma concentration in the medium is between 0% by volume and less than 4% by volume. This feature is not disclosed in D1. The medium used in D1 contains 5% serum as is evident from paragraph [0077], line 26 in connection with paragraph [0165]. Thus, new claims 1 and 15 are novel over D1.

(b) Cardarelli (D5)

In section 2.1 of the Communication original claims 1 and 19 are also objected to as lacking novelty over Cardarelli (D5), in particular the disclosure provided in the "Materials and Methods" section.

This objection does not apply to the new claims. In particular, the claims have been restricted to the use of certain fibronectin fragments. D5, however, does not disclose the use of fibronectin fragments. Thus, new claims 1 and 15 are novel over D5.

(c) US 5,354,686 (D6)

In section 2.1 of the Communication original claims 1 and 19 are also objected to as lacking novelty over US 5,354,686 (D6).

However, we submit that this novelty objection is not justified and, in particular, does not apply to the new claims for the following reasons: D6 relates to T-cells which are capable of binding to an extra-cellular matrix protein (ECM protein) such as fibronectin. However, it fails to teach or suggest effects by using fragments of fibronectin. Also, this reference merely discloses to assess the likelihood of binding of T-cells to fibronectin as ECM with serum-free cell culture medium, but it does not disclose expanding T-cells with serum-free culture medium.

Thus, new claims 1 and 15 are also novel over D6.

(d) Takashi (D7)

In section 2.1 of the Communication original claims 1 and 19 are also objected to as lacking novelty over Takashi (D7).

However, we submit that this novelty objection is not justified and does not apply to the new claims.

D7 discloses activation of T-cells by fibronectin or vitronectin. However, D7 does not disclose effects by using fragments of fibronectin. Also, serum-free medium is used in the reference only for examining SE release from cells and IL2 production. It is not disclosed to expand T-cells on serum-free medium.

Thus, new claims 1 and 15 are also novel over D7.

2.2 Original claim 17

In section 2.2 of the Communication original claim 17 is objected to as lacking novelty over Cardarelli (D5) and over US 5,354,686 (D6).

This objection does no longer apply since original claim 17 has been cancelled.

2.3 Original claims 18 and 20

In section 2.3 the Examiner also objects to original claims 18 and 20 as lacking novelty over US 5,354,686 (D6) since this document also discloses the possible use of lymphocytes in therapy and their modification by gene therapy.

As regards claim 18, this objection no longer applies since this claim has been cancelled. With respect to original claim 20 (new claim 16) the objection is not justified since this claim refers back to claim 1 which is novel over D6 as set forth in section 2.1(c), supra. Thus, the same applies to new claim 16.

2.4 Original claims 1 to 21 (new claims 1 to 17)

In section 2.4 of the Communication the Examiner cites EP-A1 1 496 109 (D2) as being novelty destroying for original claims 1 to 21. The Examiner takes the position that D2 is novelty destroying because the range of the present application is not sufficiently far from the 5% value known in the art.

This objection does not apply to the new claims because the upper level of "less than 5%" has been changed to "less than 4%".

2.5 Original claims 22 to 24 (new claims 18 to 20)

In section 2.5 of the Communication the Examiner also objects to original claims 22 to 24 as lacking novelty over WO 90/13653 (D3) and over EP-A1 207 751 (D4) arguing that certain sequences disclosed in these documents show more than 98% sequence identity to SEQ ID NO: 25 or 26.

The Applicant takes the position that this objection is not justified and does, in particular, not apply to new claims 18 to 20 which have been further specified to relate to polypeptides/nucleic acids consisting of specific sequences as defined in the claims. In this context we enclose as Annexes I and II, respectively, comparisons of SEQ ID NO: 25 and 26 with the sequences disclosed in D3 and D4, respectively.

Annex I: SEQ ID NO: 25 versus D3 (pFHDEL1)

SEQ ID NO: 25 of the present invention corresponds to only a part of the long sequence disclosed in D3. That is, as shown in Figure 1, SEQ ID NO: 25 is a fragment corresponding to the sequence of D3 positioned at 1239-1885. Accordingly, these polypeptides are quite different from each other as a substance. Further, as noted in the specification, the polypeptide of the present invention having the amino acid sequence of SEQ ID NO: 25 shows very advantageous effects in producing lymphocytes. D3 does not disclose such effects.

Annex II: SEQ ID NO: 26 versus D4 (sequence 7705)

Similar to SEQ ID NO: 25, SEQ ID NO: 26 of the present invention corresponds to only a part of the sequence disclosed in D4, and these polynucleotides are quite different from each other as a substance. Further, as noted in the specification, the polypeptide translated from the polynucleotide shows very advantageous effects in producing lymphocytes. D4 does not disclose such effects.

Thus, Applicant submits that new claims 18 to 20 are novel over D3 and D4.

3. INVENTIVE STEP (ARTICLE 56 EPC)

The claimed subject-matter also involves inventive step over the prior art.

As noted at page 5, line 10 to page 6, line 4 of the specification as "Background Art" in conventional methods for expanding large amounts of lymphocytes, culture mediums containing 5-20% by volume of serum or plasma had been used. In contrast to this, the present invention is based on the finding that the presence of certain fragments of fibronectin enables expanding cytotoxic lymphocytes at a high efficiency even with a smaller amounts of serum or plasma. The present invention is practically very advantageous in the field of cell therapy because the amount of blood from a patient in adoptive immunotherapy can be reduced by lowering the amount of serum or plasma used in the culture medium. Moreover, lymphocytes obtained by the method of the present invention highly express the IL-2 receptor, contain CD8-positive cells in a higher ration, and have higher cytotoxic activity as described at page 11, lines 7 to 13 of the specification. Thus, the present invention exhibits superior effects in the cellular medical field.

None of the above-mentioned cited references provides any hint to expand lymphocytes by lowering the amount of serum or plasma in the culture medium. Moreover, none of the cited prior art references discloses or suggests the use of fibronectin fragments for expanding the lymphocytes.

Finally, none of the cited prior art references provides any hint that any of the above-described advantageous effects as regards the obtained lymphocytes can be obtained. Thus, taken together, it has to be concluded that the claimed subject-matter involves inventive step.

4. RULE 29(3) EPC

In section 3.1 of the Communication original claims 2 to 5 are objected to as only describing an effect.

We submit that this objection is not justified and does, in particular, not apply to the new claims.

In the new claims 2 to 5 it has been clarified that the claimed method is for preparing lymphocytes having a certain property or for achieving a higher expansion.

The indication of a purpose to be achieved in a method step cannot be regarded as being unclear. Namely, it has been accepted by the case law of the Technical Boards of Appeal that a new purpose of a use (e.g. obtaining a new hitherto unrecognized effect) is a technical feature and can confer novelty and inventive step. Moreover, that the indicated effects can indeed be achieved by the claimed method is evident from the specification, e.g., page 11, lines 7 to 13 and the Examples.

5. Requests

With the above explanations and the proposed amendments to the claims, it is submitted that the Applicant has met the requirements as set forth in the Official Communication.

If, however, the Examining Division does not agree to the above, it is requested that either a further Communication pursuant to Article 96(2) EPC or a summons to attend oral proceedings according to Article 116(1) EPC be issued. If deemed expedient, an informal interview is requested. The undersigned is prepared to discuss minor amendments over the telephone.



Dr. Friederike Stolzenburg
European Patent Attorney

Encls.

New claims 1 to 20

Copy of the claims with amendments indicated

Annexes I and II

Amended Claims

1. A method for preparing cytotoxic lymphocytes characterized in that the method comprises the step of carrying out an expansion of cytotoxic lymphocytes using a medium containing serum and plasma at a total concentration of 0% by volume or more and less than 4% by volume, in the presence of a fibronectin fragment or a mixture thereof, wherein the fibronectin fragment is at least one polypeptide (m) selected from the group consisting of polypeptides having any one of the amino acid sequences shown in SEQ ID NOs: 9 to 20 and 25 of Sequence Listing, or a polypeptide comprising at least one amino acid sequence having substitution, deletion, insertion or addition of one or the plural number of amino acids in any one of said amino acid sequences, wherein the polypeptide (n) has a function equivalent to that of said polypeptide (m).
2. The method according to claim 1, wherein the method is for preparing cytotoxic lymphocytes which highly express an interleukin-2 receptor as compared to cytotoxic lymphocytes prepared in the absence of fibronectin, a fragment thereof or a mixture thereof.
3. The method according to claim 1, wherein the method is for preparing cytotoxic lymphocytes which contain CD8-positive cell in a higher ratio as compared to cytotoxic lymphocytes prepared in the absence of fibronectin, a fragment thereof or a mixture thereof.
4. The method according to claim 1, wherein the method is for being higher expansion fold as compared to that of a method for preparing cytotoxic lymphocytes in the absence of fibronectin, a fragment thereof or a mixture thereof.
5. The method according to any one of claims 1 to 4, wherein the method is for preparing cytotoxic lymphocytes the cytotoxic activity of which is enhanced or high cytotoxic activity is maintained as compared to a cytotoxic activity of cytotoxic lymphocytes prepared in the absence of fibronectin, a fragment thereof or a mixture thereof.

6. The method according to any one of claims 1 to 5, wherein the fibronectin fragment or a mixture thereof is immobilized on a solid phase.
7. The method according to claim 6, wherein the solid phase is a cell culture equipment or a cell culture carrier.
8. The method according to claim 7, wherein the cell culture equipment is a petri dish, a flask or a bag, and the cell culture carrier is beads, a membrane or a slide glass.
9. The method according to any one of claims 1 to 8, wherein the cytotoxic lymphocytes are lymphokine-activated killer cells.
10. The method according to any one of claims 1 to 9, wherein the fibronectin fragment has a cell adhesion activity and/or a heparin binding activity.
11. The method according to claim 1 which is carried out in a cell culture equipment, wherein the method satisfies the conditions of:
 - (a) a ratio of the number of cells to a culture area in the cell culture equipment at initiation of culture being 1 cell/cm² to 5 X 10⁵ cells/cm² ; and/or
 - (b) a concentration of cells in a medium at initiation of culture being 1 cell/mL to 5 X 10⁵ cells/mL.
12. The method according to claim 11, wherein the method does not require a step of diluting a cell culture solution.
13. The method according to claim 1, wherein the method comprises carrying out an expansion of cytotoxic lymphocytes in the presence of the fibronectin fragment or a mixture thereof in a cell culture equipment containing a medium, wherein the method comprises at least one step of diluting the cell culture solution, step of exchanging the medium, or step of exchanging the cell culture equipment, and wherein the culture conditions immediately after at least one step of diluting the cell culture solution, step of exchanging the medium, or step of exchanging the cell culture equipment satisfy the conditions of:

- (c) a concentration of cells in the cell culture solution being 2×10^5 cells/mL to 1×10^8 cells/mL; or
 - (d) a ratio of the number of cells in the cell culture solution to a culture area in the cell culture equipment being 1×10^5 cells/cm² to 1×10^8 cells/cm².
14. The method according to claim 1, wherein the method comprises carrying out an expansion of cytotoxic lymphocytes in the presence of the fibronectin fragment or a mixture thereof in a cell culture equipment containing a medium, wherein the method comprises at least one step of diluting the cell culture solution, step of exchanging the medium, or step of exchanging the cell culture equipment, and wherein a total concentration of serum and plasma in the medium immediately after at least one step of diluting the cell culture solution, step of exchanging the medium, or step of exchanging the cell culture equipment is same as that at initiation of the culture or lowered as compared to that at initiation of the culture.
15. A medium for culturing cytotoxic lymphocytes, characterized in that the medium comprises as an effective ingredient the fibronectin fragment or a mixture thereof, and that a total concentration of serum and plasma in the medium is 0% by volume or more and less than 4% by volume.
16. The method according to any one of claims 1 to 14, further comprising a step of transducing a foreign gene into cytotoxic lymphocytes.
17. The method according to claim 16, wherein the foreign gene is transduced using retrovirus, adenovirus, adeno-associated virus or simian virus.
18. A polypeptide consisting of the amino acid sequence (x) shown in SEQ ID NO: 25 of Sequence Listing or an amino acid sequence (y) having deletion, insertion, addition or substitution of 1-20 amino acid(s) in the amino acid sequence (x), wherein the polypeptide consisting of the amino acid sequence (y) has a function equivalent to that of the amino acid sequence (x).
19. A nucleic acid encoding the polypeptide of claim 18.
20. The nucleic acid according to claim 19, wherein the nucleic acid is (1) a DNA

consisting of the nucleotide sequence shown in SEQ ID NO: 26; or (2) a DNA consisting of a nucleotide sequence having deletion; substitution, insertion or addition of 1-60 nucleotide(s) in the nucleotide sequence shown in SEQ ID NO: 26, wherein the DNA encodes a polypeptide having a function equivalent to that of the polypeptide encoded by the DNA (1).

Amended Claim

1. A method for preparing a-cytotoxic lymphocytes characterized in that the method comprises the step of carrying out ~~at least one step selected from induction, maintenance and an~~ expansion of a-cytotoxic lymphocytes using a medium containing serum and plasma at a total concentration of 0% by volume or more and less than 45% by volume, in the presence of a fibronectin, ~~a fragment thereof or a mixture thereof,~~

wherein the fibronectin fragment is at least one polypeptide (m) selected from the group consisting of polypeptides having any one of the amino acid sequences shown in SEQ ID NOs: 9 to 20 and 25 of Sequence Listing, or a polypeptide comprising at least one amino acid sequence having substitution, deletion, insertion or addition of one or the plural number of amino acids in any one of said amino acid sequences, wherein the polypeptide (n) has a function equivalent to that of said polypeptide (m).

2. The method according to claim 1, wherein the method is for preparing cytotoxic lymphocytes which highly expresses an interleukin-2 receptor as compared to a-cytotoxic lymphocytes prepared in the absence of fibronectin, a fragment thereof or a mixture thereof.

3. The method according to claim 1, wherein the method is for preparing cytotoxic lymphocytes which contains CD8-positive cell in a higher ratio as compared to a-cytotoxic lymphocytes prepared in the absence of fibronectin, a fragment thereof or a mixture thereof.

4. The method according to claim 1, wherein the method is for being higher an-expansion fold ~~is higher as~~ compared to that of a method for preparing a-cytotoxic lymphocytes in the absence of fibronectin, a fragment thereof or a mixture thereof.

5. The method according to any one of claims 1 to 4, wherein the method is for preparing a-cytotoxic lymphocytes the cytotoxic activity of which is enhanced or high cytotoxic activity is maintained as compared to a cytotoxic activity of a-cytotoxic lymphocytes prepared in the absence

of fibronectin, a fragment thereof or a mixture thereof.

6. The method according to any one of claims 1 to 5, wherein the fibronectin, a fragment thereof or a mixture thereof is immobilized on a solid phase.

7. The method according to claim 6, wherein the solid phase is a cell culture equipment or a cell culture carrier.

8. The method according to claim 7, wherein the cell culture equipment is a petri dish, a flask or a bag, and the cell culture carrier is beads, a membrane or a slide glass.

9. The method according to any one of claims 1 to 8, wherein the cytotoxic lymphocytes are a lymphokine-activated killer cells.

~~10. The method according to any one of claims 1 to 9, wherein the fibronectin fragment is a polypeptide (m) comprising at least any one of the amino acid sequences shown in SEQ ID NOs: 1 to 8 of Sequence Listing, or a polypeptide (n) comprising at least one amino acid sequence having substitution, deletion, insertion or addition of one or the plural number of amino acids in any one of said amino acid sequences, wherein the polypeptide (n) has a function equivalent to that of said polypeptide (m).~~

1011. The method according to any one of claims 1 to 9 10, wherein the fibronectin fragment has a cell adhesion activity and/or a heparin binding activity.

~~12. The method according to claim 10, wherein the fibronectin fragment is at least one polypeptide selected from the group consisting of polypeptides having any one of the amino acid sequences shown in SEQ ID NOs: 9 to 20 and 25 of Sequence Listing.~~

1113. The method according to claim 1 which is carried out in a cell culture equipment, wherein the method satisfies the conditions of:

(a) a ratio of the number of cells to a culture area in the cell culture equipment at initiation of culture being 1 cell/cm² to 5 X 10⁵ cells/cm² ; and/or

(b) a concentration of cells in a medium at initiation of culture being 1 cell/mL to 5 X 10⁵ cells/mL.

1214. The method according to claim 1143, wherein the method does not require a step of diluting a cell culture solution.

1315. The method according to claim 1, wherein the method comprises carrying out ~~at least any one of induction, maintenance and an~~ expansion of ~~a~~-cytotoxic lymphocytes in the presence of ~~the~~ fibronectin, ~~a fragment thereof~~ or a mixture thereof in a cell culture equipment containing a medium, wherein the method comprises at least one step of diluting the cell culture solution, step of exchanging the medium, or step of exchanging the cell culture equipment, and wherein the culture conditions immediately after at least one step of diluting the cell culture solution, step of exchanging the medium, or step of exchanging the cell culture equipment satisfy the conditions of:

(c) a concentration of cells in the cell culture solution being 2 X 10⁵ cells/mL to 1 X 10⁸ cells/mL; or

(d) a ratio of the number of cells in the cell culture solution to a culture area in the cell culture equipment being 1 X 10⁵ cells/cm² to 1 X 10⁸ cells/cm².

1416. The method according to claim 1, wherein the method comprises carrying out ~~at least any one of induction, maintenance and an~~ expansion of ~~a~~-cytotoxic lymphocytes in the presence of ~~the~~ fibronectin, ~~a fragment thereof~~ or a mixture thereof in a cell culture equipment containing a medium, wherein the method comprises at least one step of diluting the cell culture solution, step of exchanging the medium, or step of exchanging the cell culture equipment, and wherein a total concentration of serum and plasma in the medium immediately after at least one step of diluting the cell culture solution, step of exchanging the medium, or step of exchanging the cell culture equipment is same as that at initiation of the culture or lowered as compared to that at initiation

of the culture.

~~17. A cytotoxic lymphocyte obtained by the method as defined in any one of claims 1 to 16.~~

~~18. A medicament comprising as an effective ingredient the cytotoxic lymphocyte obtained by the method as defined in any one of claims 1 to 16.~~

1519. A medium for culturing a-cytotoxic lymphocytes, characterized in that the medium comprises as an effective ingredient **the fibronectin**, a fragment thereof or a mixture thereof, and that a total concentration of serum and plasma in the medium is 0% by volume or more and less than 45% by volume.

1620. The method according to any one of claims 1 to 1416, further comprising a step of transducing a foreign gene into a-cytotoxic lymphocytes.

1721. The method according to claim 1620, wherein the foreign gene is transduced using retrovirus, adenovirus, adeno-associated virus or simian virus.

1822. A polypeptide ~~having~~ **consisting of** the amino acid sequence (x) shown in SEQ ID NO: 25 of Sequence Listing or an amino acid sequence (y) having deletion, insertion, addition or substitution of 1-20~~one or the plural number of~~ amino acid(s) in the amino acid sequence (x), wherein the polypeptide ~~having~~ **consisting of** the amino acid sequence (y) has a function equivalent to that of the amino acid sequence (x).

1923. A nucleic acid encoding the polypeptide of claim 1822.

2024. The nucleic acid according to claim 1923, wherein the nucleic acid ~~comprises is~~ (1) a DNA ~~comprising~~ **consisting of** the nucleotide sequence shown in SEQ ID NO: 26; ~~or~~ (2) a DNA ~~comprising~~ **consisting of** a nucleotide sequence having deletion, substitution, insertion or addition of 1-60~~one~~

~~or the plural number of nucleotide(s) in the nucleotide sequence shown in SEQ ID NO: 26, wherein the DNA encodes a polypeptide having a function equivalent to that of the polypeptide encoded by the DNA (1), or (3) a DNA which hybridizes to a DNA comprising the nucleotide sequence shown in SEQ ID NO: 26 under stringent conditions, wherein the DNA encodes a polypeptide having a function equivalent to that of the polypeptide encoded by the DNA (1).~~

CLUSTAL X (1.83) MULTIPLE SEQUENCE ALIGNMENT

File: D:\home 14362.CENTRAL f X N g b vSEQ ID NO 25 vs pFHDEL1.ps Date: Wed Aug 15 19:21:12 2007
Page 1 of 3

SEQNO.25	10	20	30	40	50	60	70	80	90	100	110	120	130	140	150
pFHDEL1	CAQCVQSQSEVA	VSGSRP	GC	PDN	CHH	QZNOCH	STH	ILGN	VVYVC	CHGDS	SENC	CHSP	RAEET	CH	CH
ruler	1	10	20	30	40	50	60	70	80	90	100	110	120	130	140
SEQNO.25	160	170	180	190	200	210	220	230	240	250	260	270	280	290	300
pFHDEL1	EAAC	CDPAAGT	SWG	STH	CH	CH	CH	CH	CH	CH	CH	CH	CH	CH	CH
ruler	1	10	20	30	40	50	60	70	80	90	100	110	120	130	140
SEQNO.25	310	320	330	340	350	360	370	380	390	400	410	420	430	440	450
pFHDEL1	ECT	CH	CH	CH	CH	CH	CH	CH	CH	CH	CH	CH	CH	CH	CH
ruler	1	10	20	30	40	50	60	70	80	90	100	110	120	130	140
SEQNO.25	460	470	480	490	500	510	520	530	540	550	560	570	580	590	600
pFHDEL1	DQ	CH	CH	CH	CH	CH	CH	CH	CH	CH	CH	CH	CH	CH	CH
ruler	1	10	20	30	40	50	60	70	80	90	100	110	120	130	140
SEQNO.25	610	620	630	640	650	660	670	680	690	700	710	720	730	740	750
pFHDEL1	AP	CH	CH	CH	CH	CH	CH	CH	CH	CH	CH	CH	CH	CH	CH
ruler	1	10	20	30	40	50	60	70	80	90	100	110	120	130	140
SEQNO.25	760	770	780	790	800	810	820	830	840	850	860	870	880	890	900
pFHDEL1	EG	CH	CH	CH	CH	CH	CH	CH	CH	CH	CH	CH	CH	CH	CH
ruler	1	10	20	30	40	50	60	70	80	90	100	110	120	130	140
SEQNO.25	910	920	930	940	950	960	970	980	990	1000	1010	1020	1030	1040	1050
pFHDEL1	BA	CH	CH	CH	CH	CH	CH	CH	CH	CH	CH	CH	CH	CH	CH
ruler	1	10	20	30	40	50	60	70	80	90	100	110	120	130	140

CLUSTAL X (1.83) MULTIPLE SEQUENCE ALIGNMENT

File: D:\home 14362.CENTRAL f X N g b vSEQ ID NO 25 vs pFHDEL1.ps Date: Wed Aug 15 19:21:12 2007
 Page 2 of 3

SEQNO. 25	1060	1070	1080	1090	1100	1110	1120	1130	1140	1150	1160	1170	1180	1190	1200
PFHDEL1	1060	1070	1080	1090	1100	1110	1120	1130	1140	1150	1160	1170	1180	1190	1200
ruler	1060	1070	1080	1090	1100	1110	1120	1130	1140	1150	1160	1170	1180	1190	1200
SEQNO. 25	1110	1120	1130	1140	1150	1160	1170	1180	1190	1200	1210	1220	1230	1240	1250
PFHDEL1	1110	1120	1130	1140	1150	1160	1170	1180	1190	1200	1210	1220	1230	1240	1250
ruler	1110	1120	1130	1140	1150	1160	1170	1180	1190	1200	1210	1220	1230	1240	1250
SEQNO. 25	1360	1370	1380	1390	1400	1410	1420	1430	1440	1450	1460	1470	1480	1490	1500
PFHDEL1	1360	1370	1380	1390	1400	1410	1420	1430	1440	1450	1460	1470	1480	1490	1500
ruler	1360	1370	1380	1390	1400	1410	1420	1430	1440	1450	1460	1470	1480	1490	1500
SEQNO. 25	1510	1520	1530	1540	1550	1560	1570	1580	1590	1600	1610	1620	1630	1640	1650
PFHDEL1	1510	1520	1530	1540	1550	1560	1570	1580	1590	1600	1610	1620	1630	1640	1650
ruler	1510	1520	1530	1540	1550	1560	1570	1580	1590	1600	1610	1620	1630	1640	1650
SEQNO. 25	1660	1670	1680	1690	1700	1710	1720	1730	1740	1750	1760	1770	1780	1790	1800
PFHDEL1	1660	1670	1680	1690	1700	1710	1720	1730	1740	1750	1760	1770	1780	1790	1800
ruler	1660	1670	1680	1690	1700	1710	1720	1730	1740	1750	1760	1770	1780	1790	1800
SEQNO. 25	1810	1820	1830	1840	1850	1860	1870	1880	1890	1900	1910	1920	1930	1940	1950
PFHDEL1	1810	1820	1830	1840	1850	1860	1870	1880	1890	1900	1910	1920	1930	1940	1950
ruler	1810	1820	1830	1840	1850	1860	1870	1880	1890	1900	1910	1920	1930	1940	1950
SEQNO. 25	1960	1970	1980	1990	2000	2010	2020	2030	2040	2050	2060	2070	2080	2090	2100
PFHDEL1	1960	1970	1980	1990	2000	2010	2020	2030	2040	2050	2060	2070	2080	2090	2100
ruler	1960	1970	1980	1990	2000	2010	2020	2030	2040	2050	2060	2070	2080	2090	2100

CLUSTAL X (1.83) MULTIPLE SEQUENCE ALIGNMENT

File: D:\home 14362.CENTRAL f X N g b vSEQ ID NO 25 vs pFHDEL1.ps Date: Wed Aug 15 19:21:12 2007
Page 3 of 3

SEQU. 25 658
pFHDEL1 EVNIGGEPDQGGNGQCHSCTGNGPDESCPPERATCPDGGTAVGSCQGLPQALGCTCTGGGGLLECONCNGRGGGFFSTGQNGNCSGSSGCTATVAVNCECTGCTDQADGDDSE 2231
ruler 2230

CLUSTAL X (1.83) MULTIPLE SEQUENCE ALIGNMENT

File: D:\home 14362.CENTRAL f X N g b vSEQ ID NO 26 vs 7705.ps Date: Wed Aug 15 19:23:04 2007
Page 1 of 8

Seq7705
ruler 1.....10.....20.....30.....40.....50.....60.....70.....80.....90.....100.....110.....120.....130.....140.....150

Seq7705
ruler160.....170.....180.....190.....200.....210.....220.....230.....240.....250.....260.....270.....280.....290.....300

Seq7705
ruler310.....320.....330.....340.....350.....360.....370.....380.....390.....400.....410.....420.....430.....440.....450

Seq7705
ruler460.....470.....480.....490.....500.....510.....520.....530.....540.....550.....560.....570.....580.....590.....600

Seq7705
ruler610.....620.....630.....640.....650.....660.....670.....680.....690.....700.....710.....720.....730.....740.....750

Seq7705
ruler760.....770.....780.....790.....800.....810.....820.....830.....840.....850.....860.....870.....880.....890.....900

Seq7705
ruler910.....920.....930.....940.....950.....960.....970.....980.....990.....1000.....1010.....1020.....1030.....1040.....1050

File: D:\home 14362.CENTRAL f X N g b vSEQ ID NO 26 vs 7705.ps
Page 2 of 8
Date: Wed Aug 15 19:23:04 2007

[illegible][illegible]

SPONS. 26
seq705 ruler 1500

82NOV.26	1650
Seq#705	1650
Seq#706	1650
Seq#707	1650
Seq#708	1650
Seq#709	1650
Seq#710	1650
Seq#711	1650
Seq#712	1650
Seq#713	1650
Seq#714	1650
Seq#715	1650
Seq#716	1650
Seq#717	1650
Seq#718	1650
Seq#719	1650
Seq#720	1650
Seq#721	1650
Seq#722	1650
Seq#723	1650
Seq#724	1650
Seq#725	1650
Seq#726	1650
Seq#727	1650
Seq#728	1650
Seq#729	1650
Seq#730	1650
Seq#731	1650
Seq#732	1650
Seq#733	1650
Seq#734	1650
Seq#735	1650
Seq#736	1650
Seq#737	1650
Seq#738	1650
Seq#739	1650
Seq#740	1650
Seq#741	1650
Seq#742	1650
Seq#743	1650
Seq#744	1650
Seq#745	1650
Seq#746	1650
Seq#747	1650
Seq#748	1650
Seq#749	1650
Seq#750	1650
Seq#751	1650
Seq#752	1650
Seq#753	1650
Seq#754	1650
Seq#755	1650
Seq#756	1650
Seq#757	1650
Seq#758	1650
Seq#759	1650
Seq#760	1650
Seq#761	1650
Seq#762	1650
Seq#763	1650
Seq#764	1650
Seq#765	1650
Seq#766	1650
Seq#767	1650
Seq#768	1650
Seq#769	1650
Seq#770	1650
Seq#771	1650
Seq#772	1650
Seq#773	1650
Seq#774	1650
Seq#775	1650
Seq#776	1650
Seq#777	1650
Seq#778	1650
Seq#779	1650
Seq#780	1650
Seq#781	1650
Seq#782	1650
Seq#783	1650
Seq#784	1650
Seq#785	1650
Seq#786	1650
Seq#787	1650
Seq#788	1650
Seq#789	1650
Seq#790	1650
Seq#791	1650
Seq#792	1650
Seq#793	1650
Seq#794	1650
Seq#795	1650
Seq#796	1650
Seq#797	1650
Seq#798	1650
Seq#799	1650
Seq#800	1650
Seq#801	1650
Seq#802	1650
Seq#803	1650
Seq#804	1650
Seq#805	1650
Seq#806	1650
Seq#807	1650
Seq#808	1650
Seq#809	1650
Seq#810	1650
Seq#811	1650
Seq#812	1650
Seq#813	1650
Seq#814	1650
Seq#815	1650
Seq#816	1650
Seq#817	1650
Seq#818	1650
Seq#819	1650
Seq#820	1650
Seq#821	1650
Seq#822	1650
Seq#823	1650
Seq#824	1650
Seq#825	1650
Seq#826	1650
Seq#827	1650
Seq#828	1650
Seq#829	1650
Seq#830	1650
Seq#831	1650
Seq#832	1650
Seq#833	1650
Seq#834	1650
Seq#835	1650
Seq#836	1650
Seq#837	1650
Seq#838	1650
Seq#839	1650
Seq#840	1650
Seq#841	1650
Seq#842	1650
Seq#843	1650
Seq#844	1650
Seq#845	1650
Seq#846	1650
Seq#847	1650
Seq#848	1650
Seq#849	1650

Seq#	705	706	707	708	709	710	711	712	713	714	715	716	717	718	719	720	721	722	723	724	725	726	727	728	729	730	731	732	733	734	735	736	737	738	739	740	741	742	743	744	745	746	747	748	749	750	751	752	753	754	755	756	757	758	759	760	761	762	763	764	765	766	767	768	769	770	771	772	773	774	775	776	777	778	779	780	781	782	783	784	785	786	787	788	789	790	791	792	793	794	795	796	797	798	799	800
Seq#	705	706	707	708	709	710	711	712	713	714	715	716	717	718	719	720	721	722	723	724	725	726	727	728	729	730	731	732	733	734	735	736	737	738	739	740	741	742	743	744	745	746	747	748	749	750	751	752	753	754	755	756	757	758	759	760	761	762	763	764	765	766	767	768	769	770	771	772	773	774	775	776	777	778	779	780	781	782	783	784	785	786	787	788	789	790	791	792	793	794	795	796	797	798	799	800

Seq	705	706	707	708	709	710	711	712	713	714	715	716	717	718	719	720	721	722	723	724	725	726	727	728	729	730	731	732	733	734	735	736	737	738	739	740	741	742	743	744	745	746	747	748	749	750	751	752	753	754	755	756	757	758	759	760	761	762	763	764	765	766	767	768	769	770	771	772	773	774	775	776	777	778	779	780	781	782	783	784	785	786	787	788	789	790	791	792	793	794	795	796	797	798	799	800	801	802	803	804	805	806	807	808	809	810	811	812	813	814	815	816	817	818	819	820	821	822	823	824	825	826	827	828	829	830	831	832	833	834	835	836	837	838	839	840	841	842	843	844	845	846	847	848	849	850	851	852	853	854	855	856	857	858	859	860	861	862	863	864	865	866	867	868	869	870	871	872	873	874	875	876	877	878	879	880	881	882	883	884	885	886	887	888	889	890	891	892	893	894	895	896	897	898	899	900	901	902	903	904	905	906	907	908	909	910	911	912	913	914	915	916	917	918	919	920	921	922	923	924	925	926	927	928	929	930	931	932	933	934	935	936	937	938	939	940	941	942	943	944	945	946	947	948	949	950	951	952	953	954	955	956	957	958	959	960	961	962	963	964	965	966	967	968	969	970	971	972	973	974	975	976	977	978	979	980	981	982	983	984	985	986	987	988	989	990	991	992	993	994	995	996	997	998	999	1000
Seq	705	706	707	708	709	710	711	712	713	714	715	716	717	718	719	720	721	722	723	724	725	726	727	728	729	730	731	732	733	734	735	736	737	738	739	740	741	742	743	744	745	746	747	748	749	750	751	752	753	754	755	756	757	758	759	760	761	762	763	764	765	766	767	768	769	770	771	772	773	774	775	776	777	778	779	780	781	782	783	784	785	786	787	788	789	790	791	792	793	794	795	796	797	798	799	800	801	802	803	804	805	806	807	808	809	810	811	812	813	814	815	816	817	818	819	820	821	822	823	824	825	826	827	828	829	830	831	832	833	834	835	836	837	838	839	840	841	842	843	844	845	846	847	848	849	850	851	852	853	854	855	856	857	858	859																																																																																																																																													

[illegible]

CLUSTAL X (1.83) MULTIPLE SEQUENCE ALIGNMENT

File: D:\home 14362.CENTRAL f X N g b vSEQ ID NO 26 vs 7705.ps Date: Wed Aug 15 19:23:04 2007
 Page 3 of 8

Seq7705 2250
 ruler 2250
 2240
 2230
 2220
 2210
 2200
 2190
 2180
 2170
 2160
 2150
 2140
 2130
 2120
 2110

Seq7705 2400
 ruler 2400
 2390
 2380
 2370
 2360
 2350
 2340
 2330
 2320
 2310
 2300
 2290
 2280
 2270
 2260

Seq7705 2550
 ruler 2550
 2540
 2530
 2520
 2510
 2500
 2490
 2480
 2470
 2460
 2450
 2440
 2430
 2420
 2410

Seq7705 2700
 ruler 2700
 2690
 2680
 2670
 2660
 2650
 2640
 2630
 2620
 2610
 2600
 2590
 2580
 2570
 2560

Seq7705 2850
 ruler 2850
 2840
 2830
 2820
 2810
 2800
 2790
 2780
 2770
 2760
 2750
 2740
 2730
 2720
 2710

Seq7705 3000
 ruler 3000
 2990
 2980
 2970
 2960
 2950
 2940
 2930
 2920
 2910
 2900
 2890
 2880
 2870
 2860

Seq7705 3150
 ruler 3150
 3140
 3130
 3120
 3110
 3100
 3090
 3080
 3070
 3060
 3050
 3040
 3030
 3020
 3010

Page 4 of 8

100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525
 526
 527
 528
 529
 530
 531
 532
 533
 534
 535
 536
 537
 538
 539
 540
 541
 542
 543
 544
 545
 546
 547
 548
 549
 550
 551
 552
 553
 554
 555
 556
 557
 558
 559
 560
 561
 562
 563
 564
 565
 566
 567
 568
 569
 570
 571
 572
 573
 574
 575
 576
 577
 578
 579
 580
 581
 582
 583
 584
 585
 586
 587
 588
 589
 590
 591
 592
 593
 594
 595
 596
 597
 598
 599
 600
 601
 602
 603
 604
 605
 606
 607
 608
 609
 610
 611

100

[The page contains extremely faint, illegible text.]

1. *What is the purpose of this document?*
 2. *What are the main findings of the study?*
 3. *What are the implications of the findings?*
 4. *What are the limitations of the study?*
 5. *What are the conclusions of the study?*
 6. *What are the recommendations for future research?*
 7. *What are the acknowledgments?*
 8. *What are the references?*
 9. *What are the appendices?*
 10. *What are the footnotes?*
 11. *What are the tables?*
 12. *What are the figures?*
 13. *What are the captions?*
 14. *What are the legends?*
 15. *What are the abbreviations?*
 16. *What are the symbols?*
 17. *What are the units?*
 18. *What are the dates?*
 19. *What are the locations?*
 20. *What are the names?*
 21. *What are the titles?*
 22. *What are the subtitles?*
 23. *What are the headings?*
 24. *What are the subheadings?*
 25. *What are the sections?*
 26. *What are the paragraphs?*
 27. *What are the sentences?*
 28. *What are the words?*
 29. *What are the letters?*
 30. *What are the numbers?*
 31. *What are the symbols?*
 32. *What are the units?*
 33. *What are the dates?*
 34. *What are the locations?*
 35. *What are the names?*
 36. *What are the titles?*
 37. *What are the subtitles?*
 38. *What are the headings?*
 39. *What are the subheadings?*
 40. *What are the sections?*
 41. *What are the paragraphs?*
 42. *What are the sentences?*
 43. *What are the words?*
 44. *What are the letters?*
 45. *What are the numbers?*
 46. *What are the symbols?*
 47. *What are the units?*
 48. *What are the dates?*
 49. *What are the locations?*
 50. *What are the names?*
 51. *What are the titles?*
 52. *What are the subtitles?*
 53. *What are the headings?*
 54. *What are the subheadings?*
 55. *What are the sections?*
 56. *What are the paragraphs?*
 57. *What are the sentences?*
 58. *What are the words?*
 59. *What are the letters?*
 60. *What are the numbers?*
 61. *What are the symbols?*
 62. *What are the units?*
 63. *What are the dates?*
 64. *What are the locations?*
 65. *What are the names?*
 66. *What are the titles?*
 67. *What are the subtitles?*
 68. *What are the headings?*
 69. *What are the subheadings?*
 70. *What are the sections?*
 71. *What are the paragraphs?*
 72. *What are the sentences?*
 73. *What are the words?*
 74. *What are the letters?*
 75. *What are the numbers?*
 76. *What are the symbols?*
 77. *What are the units?*
 78. *What are the dates?*
 79. *What are the locations?*
 80. *What are the names?*
 81. *What are the titles?*
 82. *What are the subtitles?*
 83. *What are the headings?*
 84. *What are the subheadings?*
 85. *What are the sections?*
 86. *What are the paragraphs?*
 87. *What are the sentences?*
 88. *What are the words?*
 89. *What are the letters?*
 90. *What are the numbers?*
 91. *What are the symbols?*
 92. *What are the units?*
 93. *What are the dates?*
 94. *What are the locations?*
 95. *What are the names?*
 96. *What are the titles?*
 97. *What are the subtitles?*
 98. *What are the headings?*
 99. *What are the subheadings?*
 100. *What are the sections?*
 101. *What are the paragraphs?*
 102. *What are the sentences?*
 103. *What are the words?*
 104. *What are the letters?*
 105. *What are the numbers?*
 106. *What are the symbols?*
 107. *What are the units?*
 108. *What are the dates?*
 109. *What are the locations?*
 110. *What are the names?*
 111. *What are the titles?*
 112. *What are the subtitles?*
 113. *What are the headings?*
 114. *What are the subheadings?*
 115. *What are the sections?*
 116. *What are the paragraphs?*
 117. *What are the sentences?*
 118. *What are the words?*
 119. *What are the letters?*
 120. *What are the numbers?*
 121. *What are the symbols?*
 122. *What are the units?*
 123. *What are the dates?*
 124. *What are the locations?*
 125. *What are the names?*
 126. *What are the titles?*
 127. *What are the subtitles?*
 128. *What are the headings?*
 129. *What are the subheadings?*
 130. *What are the sections?*
 131. *What are the paragraphs?*
 132. *What are the sentences?*
 133. *What are the words?*
 134. *What are the letters?*
 135. *What are the numbers?*
 136. *What are the symbols?*
 137. *What are the units?*
 138. *What are the dates?*
 139. *What are the locations?*
 140. *What are the names?*
 141. *What are the titles?*
 142. *What are the subtitles?*
 143. *What are the headings?*
 144. *What are the subheadings?*
 145. *What are the sections?*
 146. *What are the paragraphs?*
 147. *What are the sentences?*
 148. *What are the words?*
 149. *What are the letters?*
 150. *What are the numbers?*
 151. *What are the symbols?*
 152. *What are the units?*
 153. *What are the dates?*
 154. *What are the locations?*
 155. *What are the names?*
 156. *What are the titles?*
 157. *What are the subtitles?*
 158. *What are the headings?*
 159. *What are the subheadings?*
 160. *What are the sections?*
 161. *What are the paragraphs?*
 162. *What are the sentences?*
 163. *What are the words?*
 164. *What are the letters?*
 165. *What are the numbers?*
 166. *What are the symbols?*
 167. *What are the units?*
 168. *What are the dates?*
 169. *What are the locations?*
 170. *What are the names?*
 171. *What are the titles?*
 172. *What are the subtitles?*
 173. *What are the headings?*
 174. *What are the subheadings?*
 175. *What are the sections?*
 176. *What are the paragraphs?*
 177. *What are the sentences?*
 178. *What are the words?*
 179. *What are the letters?*
 180. *What are the numbers?*
 181. *What are the symbols?*
 182. *What are the units?*
 183. *What are the dates?*
 184. *What are the locations?*
 185. *What are the names?*
 186. *What are the titles?*
 187. *What are the subtitles?*
 188. *What are the headings?*
 189. *What are the subheadings?*
 190. *What are the sections?*
 191. *What are the paragraphs?*
 192. *What are the sentences?*
 193. *What are the words?*
 194. *What are the letters?*
 195. *What are the numbers?*
 196. *What are the symbols?*
 197. *What are the units?*
 198. *What are the dates?*
 199. *What are the locations?*
 200. *What are the names?*
 201. *What are the titles?*
 202. *What are the subtitles?*
 203. *What are the headings?*
 204. *What are the subheadings?*
 205. *What are the sections?*
 206. *What are the paragraphs?*
 207. *What are the sentences?*
 208. *What are the words?*
 209. *What are the letters?*
 210. *What are the numbers?*
 211. *What are the symbols?*
 212. *What are the units?*
 213. *What are the dates?*
 214. *What are the locations?*
 215. *What are the names?*
 216. *What are the titles?*
 217. *What are the subtitles?*
 218. *What are the headings?*
 219. *What*

[illegible]

1. The first part of the document is a title page. It contains the title "THE HISTORY OF THE UNITED STATES OF AMERICA" and the author "BY JAMES M. SMITH".

2. The second part of the document is a table of contents. It lists the chapters and their corresponding page numbers.

3. The third part of the document is the first chapter, titled "THE DISCOVERY OF AMERICA". It describes the early exploration of the continent by Christopher Columbus and other European navigators.

4. The fourth part of the document is the second chapter, titled "THE SETTLEMENT OF AMERICA". It discusses the early colonial settlements and the challenges faced by the settlers.

5. The fifth part of the document is the third chapter, titled "THE REVOLUTIONARY WAR". It covers the events leading up to the war and the battle of independence.

6. The sixth part of the document is the fourth chapter, titled "THE CONSTITUTION". It explains the formation of the federal government and the principles of the Constitution.

7. The seventh part of the document is the fifth chapter, titled "THE WESTERN EXPANSION". It describes the westward movement of the population and the acquisition of new territories.

8. The eighth part of the document is the sixth chapter, titled "THE CIVIL WAR". It details the conflict between the Union and the Confederacy and its impact on the nation.

9. The ninth part of the document is the seventh chapter, titled "THE RECONSTRUCTION". It discusses the efforts to rebuild the South and the challenges of integrating freed slaves into society.

10. The tenth part of the document is the eighth chapter, titled "THE MODERN UNITED STATES". It covers the period from the end of the Civil War to the present day, focusing on economic growth and social change.

File: D:\home 14362.CENTRAL f X N g b vSEQ ID NO 26 vs 7705.ps
Page 5 of 8

1. The first step in the process is to identify the problem or issue that needs to be addressed. This involves gathering information and understanding the context of the problem.

1. The first step in the process is to identify the problem or issue that needs to be addressed. This involves gathering information and understanding the context of the problem.

1
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525

1. *Introduction*
 2. *Background*
 3. *Methods*
 4. *Results*
 5. *Discussion*
 6. *Conclusion*
 7. *Acknowledgements*
 8. *References*
 9. *Appendix*
 10. *Supplementary Materials*
 11. *Tables*
 12. *Figures*
 13. *References*
 14. *Appendix*
 15. *Supplementary Materials*
 16. *Tables*
 17. *Figures*
 18. *References*
 19. *Appendix*
 20. *Supplementary Materials*
 21. *Tables*
 22. *Figures*
 23. *References*
 24. *Appendix*
 25. *Supplementary Materials*
 26. *Tables*
 27. *Figures*
 28. *References*
 29. *Appendix*
 30. *Supplementary Materials*
 31. *Tables*
 32. *Figures*
 33. *References*
 34. *Appendix*
 35. *Supplementary Materials*
 36. *Tables*
 37. *Figures*
 38. *References*
 39. *Appendix*
 40. *Supplementary Materials*
 41. *Tables*
 42. *Figures*
 43. *References*
 44. *Appendix*
 45. *Supplementary Materials*
 46. *Tables*
 47. *Figures*
 48. *References*
 49. *Appendix*
 50. *Supplementary Materials*
 51. *Tables*
 52. *Figures*
 53. *References*
 54. *Appendix*
 55. *Supplementary Materials*
 56. *Tables*
 57. *Figures*
 58. *References*
 59. *Appendix*
 60. *Supplementary Materials*
 61. *Tables*
 62. *Figures*
 63. *References*
 64. *Appendix*
 65. *Supplementary Materials*
 66. *Tables*
 67. *Figures*
 68. *References*
 69. *Appendix*
 70. *Supplementary Materials*
 71. *Tables*
 72. *Figures*
 73. *References*
 74. *Appendix*
 75. *Supplementary Materials*
 76. *Tables*
 77. *Figures*
 78. *References*
 79. *Appendix*
 80. *Supplementary Materials*
 81. *Tables*
 82. *Figures*
 83. *References*
 84. *Appendix*
 85. *Supplementary Materials*
 86. *Tables*
 87. *Figures*
 88. *References*
 89. *Appendix*
 90. *Supplementary Materials*
 91. *Tables*
 92. *Figures*
 93. *References*
 94. *Appendix*
 95. *Supplementary Materials*
 96. *Tables*
 97. *Figures*
 98. *References*
 99. *Appendix*
 100. *Supplementary Materials*
 101. *Tables*
 102. *Figures*
 103. *References*
 104. *Appendix*
 105. *Supplementary Materials*
 106. *Tables*
 107. *Figures*
 108. *References*
 109. *Appendix*
 110. *Supplementary Materials*
 111. *Tables*
 112. *Figures*
 113. *References*
 114. *Appendix*
 115. *Supplementary Materials*
 116. *Tables*
 117. *Figures*
 118. *References*
 119. *Appendix*
 120. *Supplementary Materials*
 121. *Tables*
 122. *Figures*
 123. *References*
 124. *Appendix*
 125. *Supplementary Materials*
 126. *Tables*
 127. *Figures*
 128. *References*
 129. *Appendix*
 130. *Supplementary Materials*
 131. *Tables*
 132. *Figures*
 133. *References*
 134. *Appendix*
 135. *Supplementary Materials*
 136. *Tables*
 137. *Figures*
 138. *References*
 139. *Appendix*
 140. *Supplementary Materials*
 141. *Tables*
 142. *Figures*
 143. *References*
 144. *Appendix*
 145. *Supplementary Materials*
 146. *Tables*
 147. *Figures*
 148. *References*
 149. *Appendix*
 150. *Supplementary Materials*
 151. *Tables*
 152. *Figures*
 153. *References*
 154. *Appendix*
 155. *Supplementary Materials*
 156. *Tables*
 157. *Figures*
 158. *References*
 159. *Appendix*
 160. *Supplementary Materials*
 161. *Tables*
 162. *Figures*
 163. *References*
 164. *Appendix*
 165. *Supplementary Materials*
 166. *Tables*
 167. *Figures*
 168. *References*
 169. *Appendix*
 170. *Supplementary Materials*
 171. *Tables*
 172. *Figures*
 173. *References*
 174. *Appendix*
 175. *Supplementary Materials*
 176. *Tables*
 177. *Figures*
 178. *References*
 179. *Appendix*
 180. *Supplementary Materials*
 181. *Tables*
 182. *Figures*
 183. *References*
 184. *Appendix*
 185. *Supplementary Materials*
 186. *Tables*
 187. *Figures*
 188. *References*
 189. *Appendix*
 190. *Supplementary Materials*
 191. *Tables*
 192. *Figures*
 193. *References*
 194. *Appendix*
 195. *Supplementary Materials*
 196. *Tables*
 197. *Figures*
 198. *References*
 199. *Appendix*
 200. *Supplementary Materials*
 201. *Tables*
 202. *Figures*
 203. *References*
 204. *Appendix*
 205. *Supplementary Materials*
 206. *Tables*
 207. *Figures*
 208. *References*
 209. *Appendix*
 210. *Supplementary Materials*
 211. *Tables*
 212. *Figures*
 213. *References*
 214. *Appendix*
 215. *Supplementary Materials*
 216. *Tables*
 217. *Figures*
 218. *References*
 219. *Appendix*
 220. *Supplementary Materials*
 221. *Tables*
 222. *Figures*
 223. *References*
 224. *Appendix*
 225. *Supplementary Materials*
 226. *Tables*
 227. *Figures*
 228. *References*
 229. *Appendix*
 230. *Supplementary Materials*
 231. *Tables*
 232. *Figures*
 233. *References*
 234. *Appendix*
 235. *Supplementary Materials*
 236. *Tables*
 237. *Figures*
 238. *References*
 239. *Appendix*
 240. *Supplementary Materials*
 241. *Tables*
 242. *Figures*
 243. *References*
 244. *Appendix*
 245. *Supplementary Materials*
 246. *Tables*
 247. *Figures*
 248. *References*
 249. *Appendix*
 250. *Supplementary Materials*
 25

1

1. The first part of the document is a title page. It contains the title of the document, the author's name, and the date of the document. The title is "The History of the United States of America". The author is "John Adams". The date is "1776".

Abstract—The purpose of this study was to determine whether there were differences in the prevalence of musculoskeletal disorders among different types of workers. The subjects included all employees of a large manufacturing company who had been employed for at least one year. A questionnaire was sent to each employee asking about his or her work history, symptoms of musculoskeletal disorders, and other factors. The results showed that the prevalence of musculoskeletal disorders was higher among workers in certain occupations than others. The most common disorders were low back pain, neck pain, and shoulder pain. The prevalence of these disorders was highest among workers in the assembly line occupation. The results suggest that there may be occupational factors that contribute to the development of musculoskeletal disorders.

CLUSTAL X (1.83) MULTIPLE SEQUENCE ALIGNMENT

File: D:\home 14362.CENTRAL f X N g b vSEQ ID NO 26 vs 7705.ps Date: Wed Aug 15 19:23:04 2007
 Page 6 of 8

SEQNO.263260.....3270.....3280.....3290.....3300.....3310.....3320.....3330.....3340.....3350.....3360.....3370.....3380.....3390.....3400	1409
Seq77053410.....3420.....3430.....3440.....3450.....3460.....3470.....3480.....3490.....3500.....3510.....3520.....3530.....3540.....3550	5550
ruler3560.....3570.....3580.....3590.....3600.....3610.....3620.....3630.....3640.....3650.....3660.....3670.....3680.....3690.....3700	5700
SEQNO.263710.....3720.....3730.....3740.....3750.....3760.....3770.....3780.....3790.....3800.....3810.....3820.....3830.....3840.....3850	1859
Seq77053860.....3870.....3880.....3890.....3900.....3910.....3920.....3930.....3940.....3950.....3960.....3970.....3980.....3990.....4000	6000
ruler4010.....4020.....4030.....4040.....4050.....4060.....4070.....4080.....4090.....4100.....4110.....4120.....4130.....4140.....4150	6150
SEQNO.264160.....4170.....4180.....4190.....4200.....4210.....4220.....4230.....4240.....4250.....4260.....4270.....4280.....4290.....4300	1989
Seq77054310.....4320.....4330.....4340.....4350.....4360.....4370.....4380.....4390.....4400.....4410.....4420.....4430.....4440.....4450	6300
ruler4460.....4470.....4480.....4490.....4500.....4510.....4520.....4530.....4540.....4550.....4560.....4570.....4580.....4590.....4600	6450

CLUSTAL X (1.83) MULTIPLE SEQUENCE ALIGNMENT

File: D:\home 14362.CENTRAL f X N g b vSEQ ID NO 26 vs 7705.ps Date: Wed Aug 15 19:23:04 2007
 Page 7 of 8

SEQNO. 26
 Seq7705
 ruler

.....

SEQNO. 26
 Seq7705
 ruler

.....

SEQNO. 26
 Seq7705
 ruler

.....

SEQNO. 26
 Seq7705
 ruler

.....

SEQNO. 26
 Seq7705
 ruler

.....

SEQNO. 26
 Seq7705
 ruler

.....

SEQNO. 26
 Seq7705
 ruler

.....

File: D:\home\14362.CENTRAL f X N g v\SEQ ID NO 26 vs 7705.ps
Page 8 of 8

SEQNO.	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100																																																																																																																																																																																														
Seq#705	7360	7370	7380	7390	7400	7410	7420	7430	7440	7450	7460	7470	7480	7490	7500	7510	7520	7530	7540	7550	7560	7570	7580	7590	7600	7610	7620	7630	7640	7650	7660	7670	7680	7690	7700	7710	7720	7730	7740	7750	7760	7770	7780	7790	7800	7810	7820	7830	7840	7850	7860	7870	7880	7890	7900	7910	7920	7930	7940	7950	7960	7970	7980	7990	8000	8010	8020	8030	8040	8050	8060	8070	8080	8090	8100	8110	8120	8130	8140	8150	8160	8170	8180	8190	8200	8210	8220	8230	8240	8250	8260	8270	8280	8290	8300	8310	8320	8330	8340	8350	8360	8370	8380	8390	8400	8410	8420	8430	8440	8450	8460	8470	8480	8490	8500	8510	8520	8530	8540	8550	8560	8570	8580	8590	8600	8610	8620	8630	8640	8650	8660	8670	8680	8690	8700	8710	8720	8730	8740	8750	8760	8770	8780	8790	8800	8810	8820	8830	8840	8850	8860	8870	8880	8890	8900	8910	8920	8930	8940	8950	8960	8970	8980	8990	9000	9010	9020	9030	9040	9050	9060	9070	9080	9090	9100	9110	9120	9130	9140	9150	9160	9170	9180	9190	9200	9210	9220	9230	9240	9250	9260	9270	9280	9290	9300	9310	9320	9330	9340	9350	9360	9370	9380	9390	9400	9410	9420	9430	9440	9450	9460	9470	9480	9490	9500	9510	9520	9530	9540	9550	9560	9570	9580	9590	9600	9610	9620	9630	9640	9650	9660	9670	9680	9690	9700	9710	9720	9730	9740	9750	9760	9770	9780	9790	9800	9810	9820	9830	9840	9850	9860	9870	9880	9890	9900	9910	9920	9930	9940	9950	9960	9970	9980	9990	10000

SEQNO. 26	1989
Seq7705	7650
ruler	7650
7310	7630
7520	7630
7530	7630
7540	7630
7550	7630
7560	7630
7570	7630
7580	7630
7590	7630
7600	7630
7610	7630
7620	7630
7630	7630
7640	7630
7650	7630
7660	7630
7670	7630
7680	7630
7690	7630
7700	7630
7710	7630
7720	7630
7730	7630
7740	7630
7750	7630
7760	7630
7770	7630
7780	7630
7790	7630
7800	7630
7810	7630
7820	7630
7830	7630
7840	7630
7850	7630
7860	7630
7870	7630
7880	7630
7890	7630
7900	7630
7910	7630
7920	7630
7930	7630
7940	7630
7950	7630
7960	7630
7970	7630
7980	7630
7990	7630
8000	7630

SEQNO. 26	1989
Seq7705	7705
ruler	7700